Management of Autoimmune Skin Diseases

Management of Autoimmune Skin Diseases

Management of Autoimmune Skin Diseases

On this page

Principles & Corticosteroids - First-Line Firefight

  • Management Goals:
    • Induce remission (rapid control).
    • Maintain remission, prevent flares.
    • Minimize treatment side effects.
    • Enhance Quality of Life (QoL).
  • Corticosteroids (CS): First-line; potent anti-inflammatory, immunosuppressive.
    • Topical CS:
      • Potency (mild to superpotent) based on site & severity.
      • E.g., Hydrocortisone (face), Clobetasol (palms/soles).
      • SE: Atrophy, striae, telangiectasia, tachyphylaxis. Topical Corticosteroid Potency Classes
    • Systemic CS: For severe/widespread disease.
      • Oral Prednisolone: 1-2 mg/kg/day initially, then slow taper.
      • IV Pulse Therapy (e.g., Dexamethasone-Cyclophosphamide Pulse - DCP) for aggressive forms like Pemphigus.
      • SE: Cushing's, osteoporosis, ↑infection risk, HPA axis suppression, PUD.
      • Monitor: BP, glucose, electrolytes.
    • Intralesional CS (ILCS): Localized lesions (e.g., DLE, keloids). Triamcinolone acetonide (2.5-10 mg/mL).

⭐ Prednisolone 1-1.5 mg/kg/day is the initial standard for Pemphigus Vulgaris to achieve rapid blister control.

Steroid-Sparing Agents - Backup Brigade Buddies

Use: ↓ steroids, maintain remission. Monitor labs per agent.

  • Azathioprine (AZA)
    • Purine analogue. 1-3 mg/kg/d. Onset: 6-12w.
    • SE: Myelosuppression (check TPMT), hepatotoxic, pancreatitis. ⭐ > TPMT testing vital before Azathioprine: prevents severe myelosuppression in at-risk patients.
  • Methotrexate (MTX)
    • Folate antagonist. 7.5-25 mg/wk (+folic acid). Onset: 4-8w.
    • SE: Myelosuppression, hepatotoxic, pneumonitis, teratogen.
  • Mycophenolate Mofetil (MMF)
    • IMPDH inhibitor. 1-2 g/d. Onset: 4-8w.
    • SE: GI upset, myelosuppression.
  • Cyclosporine (CsA)
    • Calcineurin inhibitor. 2.5-5 mg/kg/d. Onset: 2-4w (rapid).
    • SE: Nephrotoxic, HTN, neurotoxic.
  • Cyclophosphamide (CYC) (Severe cases)
    • Alkylating agent.
    • SE: Myelosuppression, hemorrhagic cystitis, infertility, malignancy.
  • Dapsone
    • Anti-inflammatory. 50-200 mg/d.
    • SE: Hemolysis (check G6PD), methemoglobinemia.

Biologics & IVIG - Precision Power-Ups

  • Biologics: Target refractory autoimmune skin diseases.
    • Mechanism: Target specific cytokines or immune cells.
    • Key Examples (Disease):
      • TNF-α inhibitors (Infliximab): Psoriasis, HS.
      • IL-17 inhibitors (Secukinumab): Psoriasis.
      • IL-23 inhibitors (Guselkumab): Psoriasis.
      • Rituximab (anti-CD20): Pemphigus Vulgaris (PV), Bullous Pemphigoid (BP).
      • Omalizumab (anti-IgE): Chronic Spontaneous Urticaria (CSU).
    • Pre-therapy screening: TB, Hepatitis B/C.
  • IVIG (Intravenous Immunoglobulin):
    • Mechanism: Broad immunomodulatory effects.
    • Uses: Severe PV, BP, Dermatomyositis.
    • Dose: 0.4-2 g/kg per cycle.
    • Adverse Effects: Headache, renal toxicity (sucrose preps), thrombosis. Ustekinumab Approval Timeline for Psoriasis

⭐ Rituximab significantly reduces steroid dependence in Pemphigus Vulgaris.

Adjunctive Care - Holistic Healing Hints

  • Sun Protection: Crucial for photosensitive conditions (e.g., SLE, dermatomyositis).
    • Broad-spectrum sunscreen (SPF >30, PA+++).
    • Protective clothing, seek shade.
  • Gentle Skincare:
    • Mild, non-irritant cleansers.
    • Regular use of emollients/moisturizers to maintain skin barrier.
  • Diet & Lifestyle:
    • Balanced nutrition; address deficiencies (e.g., Vitamin D).
    • Smoking cessation (worsens many conditions, e.g., DLE, psoriasis).
    • Stress reduction techniques (yoga, meditation).
  • Psychological Support: Address anxiety/depression common with chronic skin disease.
  • Physiotherapy: For joint involvement or contractures (e.g., scleroderma).
  • Vaccinations: Update as per guidelines, especially for immunosuppressed patients (avoid live vaccines during active immunosuppression).

⭐ Vitamin D supplementation is often recommended in autoimmune diseases due to its immunomodulatory effects and high prevalence of deficiency, particularly in patients with limited sun exposure or on corticosteroids. Monitor levels; aim for >30 ng/mL.

  • Regular Monitoring: For disease activity, treatment side effects, and associated comorbidities (e.g., thyroid disease in vitiligo).

High‑Yield Points - ⚡ Biggest Takeaways

  • Topical and systemic corticosteroids are primary for acute control.
  • Immunosuppressants (azathioprine, methotrexate, MMF) act as crucial steroid-sparing agents.
  • Rituximab shows high efficacy in refractory Pemphigus Vulgaris.
  • Bullous Pemphigoid typically responds to potent topical steroids or moderate systemic doses.
  • Dapsone is the mainstay treatment for Dermatitis Herpetiformis.
  • Hydroxychloroquine is key for managing Cutaneous Lupus Erythematosus.
  • Vigilant monitoring for adverse effects of immunosuppressive therapy is essential.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Management of Autoimmune Skin Diseases

Test your understanding with these related questions

What is the primary condition for which calcitriol is used as a treatment?

1 of 5

Flashcards: Management of Autoimmune Skin Diseases

1/10

_____ is an autoimmune inactivation of desmosomes between keratinocytes

TAP TO REVEAL ANSWER

_____ is an autoimmune inactivation of desmosomes between keratinocytes

Pemphigus vulgaris

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free